Zynex, Inc. (ZYXI)
NASDAQ: ZYXI · Real-Time Price · USD
1.265
-0.965 (-43.27%)
At close: Aug 1, 2025, 4:00 PM
1.270
+0.005 (0.40%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Catalent Revenue
Zynex had revenue of $22.29M in the quarter ending June 30, 2025, a decrease of -55.32%. This brings the company's revenue in the last twelve months to $144.81M, down -25.21% year-over-year. In the year 2024, Zynex had annual revenue of $192.35M with 4.36% growth.
Revenue (ttm)
$144.81M
Revenue Growth
-25.21%
P/S Ratio
0.27
Revenue / Employee
$144,808
Employees
1,000
Market Cap
38.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 192.35M | 8.03M | 4.36% |
Dec 31, 2023 | 184.32M | 26.16M | 16.54% |
Dec 31, 2022 | 158.17M | 27.87M | 21.39% |
Dec 31, 2021 | 130.30M | 50.18M | 62.63% |
Dec 31, 2020 | 80.12M | 34.65M | 76.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZYXI News
- 2 days ago - Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Zynex Reports Second Quarter 2025 Financial Results - PRNewsWire
- 12 days ago - Zynex Sets Second Quarter 2025 Earnings Call - PRNewsWire
- 4 weeks ago - Tricare Temporary Payment Suspension Update - PRNewsWire
- 4 weeks ago - Zynex Announces Steven Dyson as New CEO - PRNewsWire
- 5 weeks ago - Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis - PRNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex - GlobeNewsWire
- 3 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 19, 2025 in Zynex, Inc. Lawsuit – ZYXI - GlobeNewsWire